14th Oct 2024 08:55
(Alliance News) - GSK PLC on Monday announced it has seen promising results from clinical trials investigating a potential treatment for chronic rhinosinusitis with nasal polyps, or CRSwNP.
The London-based pharmaceutical and biotechnology company hailed positive results from phase 3 ANCHOR trials evaluating the efficacy and safety of depemokimab in comparison to a placebo in adults with CRSwNP.
CRSwNP is a chronic inflammatory sinus disease, with 80% of patients showing evidence of the type 2 airway inflammation associated with more severe diseases and symptoms.
GSK said that both the Anchor-1 and Anchor-2 trials met their co-primary endpoints of a change from baseline in total endoscopic nasal polyp score after 52 weeks, as well as a change in mean nasal obstruction score from the baseline between weeks 49 and 52.
The overall incidence and severity of treatment-emergent adverse effects across both trials were similar in patients treated with either depemokimab or placebo.
Depemokimab is not currently approved anywhere as a treatment, though its extended half-life, high potency and high-binding affinity for IL-5 means it could potentially provide sustained inhibition of inflammatory functions in patients, with dosing once every six months.
GSK Global Head of Respiratory/Immunology Research & Development Kaivan Khavandi said: "Globally, millions of people suffer from CRSwNP, the majority of whom will exhibit markers of type 2 inflammation. These patients have high corticosteroid exposure and often experience recurrence of nasal polyps following surgery.
"We're very encouraged by the results from the Anchor studies, which demonstrate the potential for depemokimab to offer targeted and sustained suppression of a key inflammatory pathway underlying nasal polyp growth and nasal obstruction. Today's data, along with recent phase 3 data in severe asthma, will be used in regulatory filings around the world."
GSK said the full results from the Anchor-1 and Anchor-2 trials will be presented at an upcoming scientific congress, at an unspecified date.
Shares in GSK were up 0.9% at 1,493.50 pence each in London on Monday morning.
By Emily Parsons, Alliance News reporter
Comments and questions to [email protected]
Copyright 2024 Alliance News Ltd. All Rights Reserved.